Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Patient-reported outcome Research (Qol, fatigue, sleep, cognition, anxiety, depression)

Ongoing (recruiting) studies/projects

Register studies

Clinical studies

    Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse.
    In cooportaion with Prof. A. Schneeweiss and Prof. R. Schlenk, National Center for Tumor Diseases (NCT), Heidelberg

  • CRAFT: NCT-PMO-1602, Metastatic or locally advanced malignancies, NCT04551521

  • NCT-PMO-1603/TOP-ART, Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies, NCT03127215

  • NCT/DKTK-PMO-1604, Metastatic and Locally Advanced NRG1-rearranged Malignancies, NCT04410653

  • CH.P.12C. (Chordoma), NCT01182779

Studies with completed recruitment and ongoing research

Studies in planning

A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients.
In cooperation with PD Dr. med. Bruno Christian Köhler, Medical University of Heidelberg

to top
powered by webEdition CMS